Northern Trust Corp Has $88.64 Million Stock Holdings in Lantheus Holdings, Inc. $LNTH

Key Points

• Northern Trust Corp reduced its holdings in Lantheus Holdings, Inc. by 0.9%, owning 908,165 shares worth approximately $88.6 million after selling 8,219 shares in Q1.
• Insider Rajiv A. Patel sold 3.37 million shares of Lantheus stock for about $189 million, resulting in a 49.18% decrease in his position.
• Lantheus reported a miss on earnings with an EPS of $1.57, falling short of analyst expectations of $1.65, and its revenue decreased 4.1% year-over-year.

Northern Trust Corp trimmed its stake in Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 0.9% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 908,165 shares of the medical equipment provider's stock after selling 8,219 shares during the quarter. Northern Trust Corp owned 1.33% of Lantheus worth $88,637,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also made changes to their positions in the stock. Aberdeen Group plc lifted its position in shares of Lantheus by 3.6% in the first quarter. Aberdeen Group plc now owns 7,416 shares of the medical equipment provider's stock worth $724,000 after purchasing an additional 257 shares in the last quarter. Dimensional Fund Advisors LP grew its stake in shares of Lantheus by 2.3% in the first quarter. Dimensional Fund Advisors LP now owns 1,378,536 shares of the medical equipment provider's stock worth $134,534,000 after acquiring an additional 31,454 shares during the last quarter. Sit Investment Associates Inc. grew its stake in shares of Lantheus by 4.4% in the first quarter. Sit Investment Associates Inc. now owns 48,090 shares of the medical equipment provider's stock worth $4,694,000 after acquiring an additional 2,040 shares during the last quarter. Boston Partners grew its stake in shares of Lantheus by 10.2% in the first quarter. Boston Partners now owns 441,581 shares of the medical equipment provider's stock worth $43,228,000 after acquiring an additional 40,784 shares during the last quarter. Finally, Russell Investments Group Ltd. grew its stake in shares of Lantheus by 204.8% in the first quarter. Russell Investments Group Ltd. now owns 51,682 shares of the medical equipment provider's stock worth $5,044,000 after acquiring an additional 34,727 shares during the last quarter. 99.06% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

LNTH has been the topic of a number of recent research reports. B. Riley decreased their price target on shares of Lantheus from $122.00 to $109.00 and set a "buy" rating on the stock in a research note on Monday, June 23rd. Wall Street Zen upgraded shares of Lantheus from a "hold" rating to a "buy" rating in a research note on Thursday, May 8th. William Blair reiterated a "market perform" rating on shares of Lantheus in a research note on Wednesday, July 16th. JMP Securities decreased their price target on shares of Lantheus from $112.00 to $73.00 and set a "market outperform" rating on the stock in a research note on Thursday, August 7th. Finally, Truist Financial set a $63.00 price target on shares of Lantheus and gave the stock a "hold" rating in a research note on Monday, August 11th. Five research analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $105.50.

Insiders Place Their Bets

In other Lantheus news, insider Rajiv A. Patel sold 3,365,000 shares of the business's stock in a transaction dated Wednesday, August 20th. The stock was sold at an average price of $56.15, for a total transaction of $188,944,750.00. Following the completion of the sale, the insider directly owned 3,477,227 shares of the company's stock, valued at approximately $195,246,296.05. The trade was a 49.18% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Farallon Partners L. L C/Ca sold 3,365,000 shares of the business's stock in a transaction dated Wednesday, August 20th. The stock was sold at an average price of $56.15, for a total value of $188,944,750.00. Following the sale, the insider directly owned 3,477,227 shares of the company's stock, valued at $195,246,296.05. This represents a 49.18% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 6,838,066 shares of company stock valued at $384,430,031. 1.50% of the stock is currently owned by insiders.

Lantheus Price Performance

Shares of Lantheus stock traded down $0.46 during trading on Friday, reaching $55.04. The company's stock had a trading volume of 530,838 shares, compared to its average volume of 1,202,330. The stock has a 50-day moving average price of $69.69 and a two-hundred day moving average price of $83.36. The company has a current ratio of 4.29, a quick ratio of 4.07 and a debt-to-equity ratio of 0.49. Lantheus Holdings, Inc. has a one year low of $47.25 and a one year high of $118.21. The stock has a market capitalization of $3.74 billion, a P/E ratio of 14.64 and a beta of 0.14.

Lantheus (NASDAQ:LNTH - Get Free Report) last released its quarterly earnings results on Wednesday, August 6th. The medical equipment provider reported $1.57 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.65 by ($0.08). Lantheus had a net margin of 17.82% and a return on equity of 34.06%. The business had revenue of $378.05 million during the quarter, compared to the consensus estimate of $389.69 million. During the same period in the prior year, the firm earned $1.80 earnings per share. The business's quarterly revenue was down 4.1% compared to the same quarter last year. As a group, sell-side analysts anticipate that Lantheus Holdings, Inc. will post 6.01 EPS for the current fiscal year.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.